Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1822]

ASCO GU 2019: Treatment and management of hormone-sensitive metastatic prostate...

Prof Karim Fizazi, Dr Eleni Efstathiou

ASCO GU 2019: Treatment and management of hormone-sensitive metastatic prostate cancer ( Prof Karim Fizazi, Dr Eleni Efstathiou )

Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma

Dr Stefanie Fischer - The Christie NHS Foundation Trust, Manchester, UK

Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma ( Dr Stefanie Fischer - The Christie NHS Foundation Trust, Manchester, UK )

KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non...

Prof David McDermott - Beth Israel Deaconess Medical Center, Boston, USA

KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma ( Prof David McDermott - Beth Israel Deaconess Medical Center, Boston, USA )

CB-839 in combination with cabozantinib in patients with clear cell and...

Prof Funda Meric-Bernstam - MD Anderson Cancer Center, Houston, USA

CB-839 in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer ( Prof Funda Meric-Bernstam - MD Anderson Cancer Center, Houston, USA )

KEYNOTE-365 Cohort A: Pembrolizumab plus olaparib in docetaxel-pretreated...

Prof Evan Yu - Fred Hutchinson Cancer Research Center, Seattle, USA

KEYNOTE-365 Cohort A: Pembrolizumab plus olaparib in docetaxel-pretreated patients with mCRPC ( Prof Evan Yu - Fred Hutchinson Cancer Research Center, Seattle, USA )

Adjuvant sequential chemotherapy plus radiotherapy for LABC after radical...

Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA

Adjuvant sequential chemotherapy plus radiotherapy for LABC after radical cystectomy: Urothelial carcinoma subgroup analysis ( Prof Brian Baumann - Washington University in St. Louis, St. Louis, USA )

ASCO GU 2019: Updates on treatment and management of bladder cancer

Professor Matthew Galsky, Professor Ananya Choudhury, Professor Joaquim...

ASCO GU 2019: Updates on treatment and management of bladder cancer ( Professor Matthew Galsky, Professor Ananya Choudhury, Professor Joaquim Bellmunt, Dr Andrea Necchi )

ASCO GU 2019: Updates on non-metastatic castration-resistant prostate cancer

Prof Karim Fizazi, Dr Eleni Efstathiou, Prof Boris Hadaschik, Prof Nicholas...

ASCO GU 2019: Updates on non-metastatic castration-resistant prostate cancer ( Prof Karim Fizazi, Dr Eleni Efstathiou, Prof Boris Hadaschik, Prof Nicholas Mottet )

Analysis of acute toxicity from PACE-B: Comparing SBRT to CFMHRT for localised...

Dr Nicholas van As - The Royal Marsden NHS Foundation Trust, London, UK

Analysis of acute toxicity from PACE-B: Comparing SBRT to CFMHRT for localised prostate cancer ( Dr Nicholas van As - The Royal Marsden NHS Foundation Trust, London, UK )

Updates on metastatic bladder cancer from ASCO GU 2019

Prof Arlene Siefker-Radtke - MD Anderson Cancer Center, Houston, USA

Updates on metastatic bladder cancer from ASCO GU 2019 ( Prof Arlene Siefker-Radtke - MD Anderson Cancer Center, Houston, USA )

KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell...

Prof Brian Rini - Cleveland Clinic, Cleveland, USA

KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma ( Prof Brian Rini - Cleveland Clinic, Cleveland, USA )

ASCO GU 2019 renal highlights

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

ASCO GU 2019 renal highlights ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer